Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

@article{Belshe2001SafetyAI,
  title={Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.},
  author={Robert B. Belshe and Craig Stevens and Geoffrey J Gorse and Susan P Buchbinder and Kent J. Weinhold and Haynes Sheppard and Don M Stablein and Steve Self and James Mcnamara and Sharon E. Frey and Jorge Flores and John Louis Excler and Michel C. A. Klein and Raphaelle El Habib and Anne Marie Duliege and Clayton Harro and Lawrence Corey and Michael C. Keefer and Mark M. Mulligan and P. Wright and Connie L Celum and Franklyn Judson and Kenneth Mayer and David J. McKirnan and Michael J Marmor and George W Woody},
  journal={The Journal of infectious diseases},
  year={2001},
  volume={183 9},
  pages={1343-52}
}
Live attenuated viral vectors that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines to prevent HIV infection. The first phase 2 trial with a canarypox vector (vCP205, which expresses gp120, p55, and protease) was conducted in 435 volunteers with and without gp120 boosting, to expand the safety database and to compare the immunogenicity of the vector in volunteers who were at higher risk with that in volunteers at lower risk for HIV infection… CONTINUE READING